# BioNTech SE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biontech-se

- Industry: Biotechnology
- Headquarters: Mainz, Germany
- Website: www.biontech.de
- Total disclosed funding: $619M
- Latest round: Series B (Jul 9, 2019)
- Investors on record: 12

## About

BioNTech SE is a biotechnology company specializing in the development of immunotherapies and mRNA vaccines, dedicated to enhancing global health through innovative treatments.Founded in 2008 in Mainz, Germany, BioNTech SE focuses on developing targeted immunotherapies and mRNA vaccines. The company was co-founded by Christoph Huber and Ugur Sahin, who have backgrounds in biopharmaceutical innovation. BioNTech has raised a total of USD 1,500.00 mn across various funding rounds, with the latest being a PIPE round amounting to USD 150.00 mn.BioNTech concentrates on creating innovative immunotherapies and mRNA vaccines that aim to improve global health outcomes. Their oncology portfolio features three therapeutic modalities: mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, all designed for precise cancer cell targeting. The company’s mRNA vaccine technology gained prominence with their COVID-19 vaccine, establishing a strong presence in the infectious diseases sector. BioNTech distributes its products primarily in North America and Europe, targeting oncologists and healthcare institutions.In 2023, BioNTech reported a revenue of USD 3,539.54 mn and an EBITDA of USD 805.30 mn, primarily generated through the sales of its proprietary immunotherapy products and mRNA vaccines, including the COVID-19 vaccine BNT162b2 developed in collaboration with Pfizer.BioNTech aims to expand its product pipeline with upcoming launches in cancer immunotherapy and infectious disease vaccines. The company is exploring new markets in Asia and Latin America, with planned expansions through 2024. Recent funding from the PIPE round will support these initiatives, facilitating the development and commercialization of new therapeutic options.

## Funding rounds

- Series B, Jul 9, 2019, $325M — Invus [DUP], Platinum Asset Management, Fidelity Investments, BVCF Capital, Redmile Group, Mirae Asset Venture Investment, Pratama Capital Assets Management, The Struengmann Family Office, Jebsen Capital, Steam Athena Capital
- Series A, Jan 4, 2018, $270M — Invus [DUP], Fidelity Investments, Janus Henderson Investors, Redmile Group, The Struengmann Family Office
- Seed, Sep 1, 2008, $24M — MIG Capital, The Struengmann Family Office

## Investors

- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Seed
- The Struengmann Family Office — Seed, Series A, Series B
- Invus [DUP] — Series A, Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A, Series B
- Janus Henderson Investors — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A, Series B
- Platinum Asset Management — Series B
- BVCF Capital — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Pratama Capital Assets Management — Series B
- Jebsen Capital (https://capitalatlas.ai/funds/jebsen-capital) — Series B
- Steam Athena Capital — Series B